MSB 3.21% $1.13 mesoblast limited

2024 Here we go again., page-523

  1. 4,194 Posts.
    lightbulb Created with Sketch. 5493
    Yes,

    to Clarify these are the numbers

    11,000 transplants completed annually, along with baseline immunosuppresants administered.

    5,500 of those ( about 50% ), develop aGvHD, with around 1200 being children.

    First line approved treatment
    Adults recieve "optimised" - ( More ) steroids and immunosupressants.
    Children have nothing approved, but may get the same as the adults seeing as nothing is approved.

    Second line treatments
    Adults recieve anything ( these are not approved either ) , there is not " standard" second line. It could be MSC, different steroids, green tea, Reg's poems, anything.


    After completeing the first / second line treatment lines approximately 600 children, and 3000 adults remain as non responders. ( Nothing has worked ).
    These are in my opinion the most needy candidates for off label, as without some treatment that works - death will occur.
    That would equate to around 2 Billion USD in sales if all 3600 were treated with the pricing assumptions of 400,000 child, 600,000 adult.

    Last edited by dachopper: 18/04/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
0.035(3.21%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.09 $1.13 $1.07 $3.910M 3.535M

Buyers (Bids)

No. Vol. Price($)
2 27197 $1.11
 

Sellers (Offers)

Price($) Vol. No.
$1.13 43578 3
View Market Depth
Last trade - 16.10pm 27/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.